Jobs / United States / Glaxosmithkline LLC
Vice President - Oncology Clinical Development, Disease Area Head- Hematology
Glaxosmithkline LLC · 🇺🇸 5 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles1 certified filing for “Sr Manager - Oncology Commercial Analytics, Multiple Myeloma” (Data Scientists) in PA: $135k–$135k, median $135k. Most were filed at wage level III (100%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
Business Introduction At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success. We’re uniting science, technology, and talent to get ahead of disease together. Find out more: Our approach to R&D Please note: F or candidates seeking to be located at our Stevenage site, this role will temporarily be based at Stevenage. However, the Company plans to relocate its offices to Cambridge, UK. The location of this role will therefore subsequently change to Cambridge, UK in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029 . Position Summary: GSK is seeking to appoint a VP, Oncology Clinical Development Disease Area Head, reporting to the SVP, Head of Oncology Clinical Development. With accountability for the planning and implementation of the clinical development strategy across the Hematology portfolio, you will lead and contribute to strategic clinical positioning of early- and late-phase assets across their life-cycle with a cross-functional matrix team, at a pivotal moment for the organization as it sharpens its focus on pace, performance, portfolio delivery and bringing differentiated medicines to patients. This role requires an experienced, cross-matrix senior leader capable of implementing and executing an integrated clinical strategy in support of the successful clinical development, translational research, regulatory filing and initial market launch of a growing portfolio of innovative and transformational Oncology therapies. Key Responsibilities in Detail l Clinical Development Strategy & Portfolio Leadership Accountable for end-to-end clinical development of oncology assets from first-in-human (FTIH) studies through proof-of-concept studies, registrational trials, regulatory approval, and initial market launch, ensuring scientific rigor, speed, and quality of execution. Shape and drive the scientific and clinical development strategy for assigned disease areas and assets, aligned with Oncology Tumor Team strategy and broader Oncology portfolio priorities. Ensure deep integration of clinical, and disease-area expertise into preclinical and translational research activities to optimize asset positioning, biomarker strategy, and development strategy and decisions. Evaluate, champion, and enable the use of novel approaches (e.g., AI/ML, innovative trial designs, external and real-world data sources) where they add clear scientific, operational, or decision-making value to clinical development. Program Oversight, Governance & Visibility Provide program-level oversight and leadership, while ensuring connectedness both cross functionally and across assets, maintaining visibility to progress, risks, dependencies, and trade-offs across the Oncology portfolio. Serve as the senior clinical representative at key governance forums for assigned programs, ensuring strong clinical leadership, continuity, and high-quality decision-making. Represent the Oncology Clinical Development organization internally and externally, including presenting at high-impact forums such as congress all-hands, senior leadership reviews, and advisory boards. Lead scientific advisory boards and other external engagements to inform asset strategy, competitive positioning, and portfolio decisio